Page 443 - Read Online
P. 443

Page 10 of 15                                    Safa. J Cancer Metastasis Treat 2020;6:36  I  http://dx.doi.org/10.20517/2394-4722.2020.55

               Financial support and sponsorship
               None.


               Conflicts of interest
               The author declared that there are no conflicts of interest.


               Ethical approval and consent to participate
               Not applicable.


               Consent for publication
               Not applicable.

               Copyright
               © The Author(s) 2020.


               REFERENCES
               1.   Aier I, Semwal R, Sharma A, Varadwaj PK. A systematic assessment of statistics, risk factors, and underlying features involved in
                   pancreatic cancer. Cancer Epidemiol 2019;58:104-10.
               2.   Sohal DP, Mangu PB, Khorana AA, Shah MA, Philip PA, et al. Metastatic pancreatic cancer: American Society of Clinical Oncology
                   clinical practice guideline. J Clin Oncol 2016;34:2784-96.
               3.   Kleeff J, Korc M, Apte M, La Vecchia C, Johnson CD, et al. Pancreatic cancer. Nat Rev Dis Primers 2016;2:16022.
               4.   Balic A, Dorado J, Alonso-Gómez M, Heeschen C. Stem cells as the root of pancreatic ductal adenocarcinoma. Exp Cell Res
                   2012;318:691-4.
               5.   Hassanein MK, Suetsugu A, Saji S, Moriwaki H, Bouvet M, et al. Stem-like and non-stem human pancreatic cancer cells distinguished by
                   morphology and metastatic behavior. J Cell Biochem 2011;112:3549-54.
               6.   Berlin JD, Catalano P, Thomas JP, Kugler JW, Haller DG, et al. Phase III study of gemcitabine in combination with fluorouracil versus
                   gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol
                   2002;20:3270-5.
               7.   Singh RR, O’Reilly EM. New treatment strategies for metastatic pancreatic ductal adenocarcinoma. Drugs 2020;80:647-69.
               8.   Lambert A, Gavoille C, Conroy T. Current status on the place of FOLFIRINOX in metastatic pancreatic cancer and future directions.
                   Therap Adv Gastroenterol 2017;10:631-45.
               9.   Adamska A, Elaskalani O, Emmanouilidi A, Kim M, Abdol Razak NB, et al. Molecular and cellular mechanisms of chemoresistance in
                   pancreatic cancer. Adv Biol Regul 2018;68:77-87.
               10.  Hermann PC, Sainz B Jr. Pancreatic cancer stem cells: a state or an entity? Semin Cancer Biol 2018;53:223-31.
               11.  Sergeant G, Vankelecom H, Gremeaux L, Topal B. Role of cancer stem cells in pancreatic ductal adenocarcinoma. Nat Rev Clin Oncol
                   2009;6:580-6.
               12.  Bednar F, Simeone DM. Pancreatic cancer stem cells and relevance to cancer treatments. Cell Biochem 2009;107:40-5.
               13.   Dembinski JL, Krauss S. Characterization and functional analysis of a slow cycling stem cell-like subpopulation in pancreas
                   adenocarcinoma. Clin Exp Metastasis 2009;26:611-23.
               14.   Vaz AP, Ponnusamy MP, Seshacharyulu P, Batra SK. A concise review on the current understanding of pancreatic cancer stem cells. J
                   Cancer Stem Cell Res 2014; 2:e1004.
               15.  Mu W, Wang Z, Zöller M. Ping-pong-tumor and host in pancreatic cancer progression. Front Oncol 2019;9:1359.
               16.  Tsai KK, Chan TS, Shaked Y. Next viable routes to targeting pancreatic cancer stemness: learning from clinical setbacks. J Clin Med
                   2019;8:702.
               17.  Gzil A, Zarębska I, Bursiewicz W, Antosik P, Grzanka D, et al. Markers of pancreatic cancer stem cells and their clinical and therapeutic
                   implications. Mol Biol Rep 2019;46:6629-45.
               18.  Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc
                   Natl Acad Sci U S A 2003;100:3983-8.
               19.  Shah AN, Summy JM, Zhang J, Park SI, Parikh NU, et al. Development and characterization of gemcitabine-resistant pancreatic tumor
                   cells. Ann Surg Oncol 2007;14:3629-37.
               20.  Hermann PC, Huber SL, Heeschen C. Metastatic cancer stem cells: a new target for anti-cancer therapy? Cell Cycle 2008;7:188-93.
               21.   Steinbichler TB, Dudás J, Skvortsov S, Ganswindt U, Riechelmann H, et al. Therapy resistance mediated by cancer stem cells. Semin
                   Cancer Biol 2018;53:156-67.
               22.   Safa AR. Resistance to drugs and cell death in cancer stem cells (CSCs). J Transl Sci 2019;5:1-10.
               23.  Safa AR, Saadatzadeh MR, Cohen-Gadol AA, Pollok KE, Bijangi-Vishehsaraei K. Glioblastoma stem cells (GSCs) epigenetic plasticity
                   and interconversion between differentiated non-GSCs and GSCs. Genes Dis 2015;2:152-63.
   438   439   440   441   442   443   444   445   446   447   448